Company overview
Elixirgen Therapeutics develops cell and gene therapies for rare diseases and aging-associated conditions using proprietary ZSCAN4 technology for telomere extension and mRNA platforms like Bobcat mRNA and controllable self-replicating RNA. Their lead candidate EXG-34217, an autologous cell therapy for telomere biology disorders, has FDA RMAT designation and positive Phase I/II data showing sustained telomere elongation. The company also advances RNA vaccine technologies and large protein delivery for applications in muscular dystrophy and infectious diseases.
Elixirgen Therapeutics is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include zscan4 technology, telomere therapy, gene therapy, mrna platform, rare diseases.
Structured facts
- Website
- https://elixirgentx.com
- Markets served
- United States & Americas
- Keywords
- zscan4 technology, telomere therapy, gene therapy, mrna platform, rare diseases
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What is Elixirgen Therapeutics' core technology?
- Proprietary ZSCAN4 technology enables telomerase-independent telomere extension to restore stem cell potency, used in EXG-34217 for telomere biology disorders.
- What is the clinical status of EXG-34217?
- Phase I/II trial (NCT04211714) ongoing at Cincinnati Children’s, with early data showing sustained telomere elongation in patients and FDA RMAT designation.
- What mRNA platforms does Elixirgen offer?
- Bobcat mRNA for large proteins like full-length dystrophin, controllable self-replicating RNA (c-srRNA) with temperature regulation, and ZSCAN4 via RNA virus for genetic therapies.
Related editorial coverage
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives
- Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
- $2M Gene Therapy Cures Need a Financing Model
- Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
- Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
- FDA Issues June 2026 Guidance: Gene Therapy, Payor Comms, and CMC Flexibilities
Explore lab tools and QA/QC resources for R&D teams.
